organization · Reporting owner

Decheng Capital China Life Sciences USD Fund II, L.P.

Disclosed activity across 1 company

Tapewire entity: 74131
SEC CIK: 0001650291

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

No relationships currently tracked through insider filings.

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

No balances currently tracked through insider filings.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BeyondSpring Inc.

Report date October 16, 2025 · Filed October 21, 2025

Jointly reported with Decheng Capital China Life Sciences USD Fund III, L.P., Decheng Capital Management III (Cayman), LLC, Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin

Section 16 reporting ended · disclosed 2025-10-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Decheng Capital China Life Sciences USD Fund III, L.P.	1,518,893	Last balance in matching sequence After 2025-10-17 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2025-10-16 · Sale · Disposed 85,798 · Balance 1,564,406 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 2 · 2025-10-17 · Sale · Disposed 45,513 · Balance 1,518,893 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Decheng Capital China Life Sciences USD Fund II, L.P.	1,617,409	Reported balance Holding disclosure · report date 2025-10-16 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,617,409 F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Decheng Capital Global Healthcare Fund (Master), LP	891,734	Reported balance Holding disclosure · report date 2025-10-16 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 891,734 F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 17, 2025 Filed Oct 21, 2025 00:00 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	45,513	$1.76	$80,102.88	Disclosure SEC source: 0001231919-25-000335 · form4-10202025_111053.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,518,893 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 16, 2025 Filed Oct 21, 2025 00:00 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	85,798	$1.72	$147,572.56	Disclosure SEC source: 0001231919-25-000335 · form4-10202025_111053.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,564,406 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 15, 2025 Filed Oct 16, 2025 00:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	17,960	$1.65	$29,634.00	Disclosure SEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,650,204 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 14, 2025 Filed Oct 16, 2025 00:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	28,495	$1.65	$47,016.75	Disclosure SEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,668,164 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 13, 2025 Filed Oct 16, 2025 00:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	107,361	$1.70	$182,513.70	Disclosure SEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,696,659 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 10, 2025 Filed Oct 10, 2025 21:58 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,390	$1.77	$4,230.30	Disclosure SEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,804,020 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 09, 2025 Filed Oct 10, 2025 21:58 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,979	$1.81	$7,201.99	Disclosure SEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,806,410 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 08, 2025 Filed Oct 10, 2025 21:58 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	7,507	$1.77	$13,287.39	Disclosure SEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,810,389 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.805 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 07, 2025 Filed Oct 7, 2025 22:14 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,100	$1.79	$3,759.00	Disclosure SEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,817,896 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 06, 2025 Filed Oct 7, 2025 22:14 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	17,500	$1.78	$31,150.00	Disclosure SEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,819,996 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.7879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 03, 2025 Filed Oct 7, 2025 22:14 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	600	$1.76	$1,056.00	Disclosure SEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,837,496 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 02, 2025 Filed Oct 3, 2025 00:51 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	600	$1.73	$1,038.00	Disclosure SEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,838,096 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
October 01, 2025 Filed Oct 3, 2025 00:51 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,601	$1.80	$4,681.80	Disclosure SEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,838,696 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.785 to $1.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 30, 2025 Filed Oct 3, 2025 00:51 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	4,464	$1.81	$8,079.84	Disclosure SEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,841,297 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 29, 2025 Filed Sep 30, 2025 00:06 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	500	$1.75	$875.00	Disclosure SEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,845,761 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 26, 2025 Filed Sep 30, 2025 00:06 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	600	$1.68	$1,008.00	Disclosure SEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,846,261 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 25, 2025 Filed Sep 30, 2025 00:06 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	700	$1.66	$1,162.00	Disclosure SEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,846,861 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 24, 2025 Filed Sep 24, 2025 22:49 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,256	$1.68	$3,790.08	Disclosure SEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,847,561 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 23, 2025 Filed Sep 24, 2025 22:49 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	4,106	$1.72	$7,062.32	Disclosure SEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,849,817 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 22, 2025 Filed Sep 24, 2025 22:49 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	5,410	$1.83	$9,900.30	Disclosure SEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,853,923 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 19, 2025 Filed Sep 19, 2025 22:03 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,656	$1.79	$6,544.24	Disclosure SEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,859,333 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 18, 2025 Filed Sep 19, 2025 22:03 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	5,307	$1.74	$9,234.18	Disclosure SEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,862,989 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 17, 2025 Filed Sep 19, 2025 22:03 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,304	$1.83	$4,216.32	Disclosure SEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,868,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 16, 2025 Filed Sep 16, 2025 23:45 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	840	$1.88	$1,579.20	Disclosure SEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,870,600 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 15, 2025 Filed Sep 16, 2025 23:45 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,570	$1.84	$4,728.80	Disclosure SEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,871,440 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 12, 2025 Filed Sep 16, 2025 23:45 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	700	$1.85	$1,295.00	Disclosure SEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,874,010 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.83 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 11, 2025 Filed Sep 11, 2025 23:43 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,820	$1.90	$7,258.00	Disclosure SEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,874,710 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 10, 2025 Filed Sep 11, 2025 23:43 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	8,176	$1.93	$15,779.68	Disclosure SEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,878,530 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 09, 2025 Filed Sep 11, 2025 23:43 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	9,050	$1.97	$17,828.50	Disclosure SEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,886,706 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 08, 2025 Filed Sep 8, 2025 22:55 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	7,090	$1.93	$13,683.70	Disclosure SEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,895,756 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 05, 2025 Filed Sep 8, 2025 22:55 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	1,106	$1.86	$2,057.16	Disclosure SEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,902,846 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 04, 2025 Filed Sep 8, 2025 22:55 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	803	$1.82	$1,461.46	Disclosure SEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,903,952 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 03, 2025 Filed Sep 3, 2025 23:57 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	1,270	$1.81	$2,298.70	Disclosure SEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,904,755 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
September 02, 2025 Filed Sep 3, 2025 23:57 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,800	$1.78	$4,984.00	Disclosure SEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,906,025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 29, 2025 Filed Sep 3, 2025 23:57 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	800	$1.74	$1,392.00	Disclosure SEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,908,825 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 28, 2025 Filed Aug 29, 2025 00:39 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	809	$1.81	$1,464.29	Disclosure SEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,909,625 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 27, 2025 Filed Aug 29, 2025 00:39 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	1,300	$1.78	$2,314.00	Disclosure SEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,910,434 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 26, 2025 Filed Aug 29, 2025 00:39 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,000	$1.79	$3,580.00	Disclosure SEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,911,734 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 25, 2025 Filed Aug 25, 2025 23:46 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	300	$1.77	$531.00	Disclosure SEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,913,734 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 22, 2025 Filed Aug 25, 2025 23:46 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,376	$1.75	$4,158.00	Disclosure SEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,914,034 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 21, 2025 Filed Aug 25, 2025 23:46 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,034	$1.79	$5,430.86	Disclosure SEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,916,410 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 20, 2025 Filed Aug 20, 2025 22:35 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,456	$1.74	$6,013.44	Disclosure SEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,919,444 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 19, 2025 Filed Aug 20, 2025 22:35 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	3,604	$1.77	$6,379.08	Disclosure SEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,922,900 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 18, 2025 Filed Aug 20, 2025 22:35 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	47,668	$2.03	$96,766.04	Disclosure SEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,926,504 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 15, 2025 Filed Aug 15, 2025 23:11 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,900	$2.00	$5,800.00	Disclosure SEC source: 0001415889-25-022119 · form4-08152025_110853.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,974,172 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 14, 2025 Filed Aug 15, 2025 23:11 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,000	$2.00	$4,000.00	Disclosure SEC source: 0001415889-25-022119 · form4-08152025_110853.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,977,072 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares vat each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
August 04, 2025 Filed Aug 11, 2025 21:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	2,196	$2.18	$4,787.28	Disclosure SEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 17 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 891,734 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
July 18, 2025 Filed Aug 11, 2025 21:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	900	$2.20	$1,980.00	Disclosure SEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 16 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 893,930 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
July 17, 2025 Filed Aug 11, 2025 21:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	20,572	$2.19	$45,052.68	Disclosure SEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 15 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 894,830 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document
July 16, 2025 Filed Aug 11, 2025 21:07 UTC	BeyondSpring Inc. BYSI · Entity 7539	SaleOrdinary Shares	5,396	$2.24	$12,087.04	Disclosure SEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 14 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 915,402 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.